Literature DB >> 19683181

Extrapolating anti-vascular endothelial growth factor therapy into pediatric ophthalmology: promise and concern.

Robert L Avery.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19683181     DOI: 10.1016/j.jaapos.2009.06.003

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


× No keyword cloud information.
  5 in total

1.  Intravitreal bevacizumab in retinopathy of prematurity: an interventional case series.

Authors:  Ramak Roohipoor; Hamed Ghasemi; Fariba Ghassemi; Reza Karkhaneh; Mohammad Riazi-Esfahani; Mehdi Nili-Ahmadabadi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-04-15       Impact factor: 3.117

2.  Choroidal neovascularization in 36 eyes of children and adolescents.

Authors:  P Rishi; A Gupta; E Rishi; B J Shah
Journal:  Eye (Lond)       Date:  2013-07-26       Impact factor: 3.775

3.  Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage.

Authors:  Hossein Nazari; Mehdi Modarres; Mohammad Mehdi Parvaresh; Khalil Ghasemi Falavarjani
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-06-27       Impact factor: 3.117

4.  Long-term results of intravitreal ranibizumab for osteoma-related choroidal neovascularization in a child.

Authors:  Aditi Gupta; Lingam Gopal; Parveen Sen; Dhanashree Ratra; Chetan Rao
Journal:  Oman J Ophthalmol       Date:  2014-05

Review 5.  What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?

Authors:  Robert L Avery
Journal:  Br J Ophthalmol       Date:  2013-12-10       Impact factor: 4.638

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.